June #196 : Big Pharma Plotted to Prop Up South African Drug Patents - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


POZ at 20

From the Editor

Alive and Kicking


Letters-June 2014


Survival by Design

POZ Planet

Meet the New AIDS Poster Child

POZ Stories: Byanca Parker

What’s the Diagnosis?

The State of Louisiana

I Have Something to Tell You

Say What? Egyptian Army Edition

Preppy Style

Law & Order

Positive Leadership


The New War

Care and Treatment

Seeing the Doctor Is Vital When CD4s Are Low

HIV Rates in Black MSM Linked to STIs and Economics

Inflammatory Marker Linked to Raised Risk of Death

Big Pharma Plotted to Prop Up South African Drug Patents

Half-baked Headlines Claim that Pot Stops HIV

Research Notes

Prevention: Genetically Tooled Antibodies Fight HIV

Treatment: Benefit of Counseling With Computers

Cure: Memory Stem Cells: Reservoir Backbone?

Concerns: Youths With HIV Enter Care Late

POZ Survey Says

Have You Been Tested?

POZ Heroes

Flesh and Blood

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2014

Big Pharma Plotted to Prop Up South African Drug Patents

by Benjamin Ryan

A leaked email shows that the Innovative Pharmaceuticals Association of South Africa (IPASA) colluded with the U.S.-based pharmaceutical industry lobbying group PhRMA in an apparently successful plot to derail reforms to South Africa’s liberal patent laws. HIV advocates have sought these legal changes for years in hopes of bringing down costs for, and thus likely improving access to, antiretrovirals (ARV) for HIV in that hard-hit nation.

IPASA reps ARV-producing companies such as Merck, Sanofi, Pfizer, Roche and Novartis.

An email sent by Michael Azrak, the managing director of Merck Southern and East Africa and the head of IPASA’s intellectual property committee, indicated that IPASA, in consultation with PhRMA, engaged consultancy group Public Affairs Engagement to influence the intellectual property reform process in South Africa. All this was in contrast to IPASA’s previous denials.

Despite a media firestorm—which landed the affair with the moniker “Pharmagate”—the South African cabinet still did not bring the reform package to a vote before the May 7 national elections, leaving it in limbo for the near future.

“We’re concerned the plots may have worked, that the government may have bowed to pressure,” says Lotti Rutter, a senior researcher at the Treatment Action Campaign in South Africa.

IPASA’s actions, Rutter says, represent “just a shocking disregard for human life in South Africa.”

Search: Innovative Pharmaceuticals Association of South Africa, PhRMA, South Africa, drug patents

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.